RFK JR: “Tony Fauci Knew That Remdesivir Would Kill You” “How does it kill you?” he asked. “Kidney failure, heart failure, and all-organ collapse.” “All the doctors said … ‘We’ve never seen a virus that attacks the kidneys.’ Because it wasn’t the virus; it was the remdesivir.” The truth about COVID that never got out to the public is that hospitals weren’t treating COVID patients; they were murdering them. Why? Because the government incentivized them to do it. • $13,000 per each “COVID” patient • $39,000 for putting a COVID patient on the vent • Plus, HHS added a 20% bonus on the entire hospital bill if they administered Remdesivir, a drug so toxic it earned the infamous nickname, “Run Death Is Near.” If this is the first time you’re hearing any of this, there’s a reason. The Biden Administration infringed on our First Amendment rights and pressured social media companies to CENSOR truthful information about COVID.

The Remdesivir Story: From Potential Breakthrough to Controversy

In April 2020, remdesivir, an antiviral medication developed through a partnership between Gilead Sciences and researchers at the University of North Carolina at Chapel Hill, emerged as a potential treatment for COVID-19. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), stated that data from clinical trials showed the drug had a “clear-cut significant positive effect” in diminishing the time to recovery for patients. This initial optimism positioned remdesivir as a potential standard of care.

The Development and Early Trials of Remdesivir

The drug’s origins trace back to research initiated in 2009, initially focused on treatments for hepatitis C and respiratory syncytial virus. Clinical trials, including those led by NIAID, indicated that patients receiving a 5-day course of remdesivir generally recovered faster than those receiving a placebo – 11 days versus 15 days. This finding prompted discussions about rapidly making the drug available to a wider patient population.

Shifting Narratives and Emerging Concerns

Despite the initial positive outlook, questions and controversies surrounding remdesivir began to surface. Recent claims, as highlighted in social media posts, allege that Dr. Fauci was aware of potentially fatal side effects associated with the drug, including kidney failure, heart failure, and organ collapse. These claims also suggest financial incentives existed for hospitals to administer remdesivir, with additional payments for ventilation and a bonus for using the drug itself.

Debunking Misinformation: Fauci and Remdesivir

FactCheck.org investigated claims that Dr. Fauci “invented” remdesivir with Bill Gates and stood to profit from its use. Their investigation found these claims to be false. Remdesivir was invented by Gilead Sciences, and any profits from its sales accrue to the pharmaceutical company, not Dr. Fauci or the NIH. Dr. Fauci has been listed as an inventor on patents for other drugs through his work at the National Institute of Allergy and Infectious Diseases, but not for remdesivir.

The Role of Financial Incentives in Treatment Protocols

The allegations regarding financial incentives for hospitals to use remdesivir raise important questions about the influence of economic factors on medical decision-making during a pandemic. The claims suggest hospitals received $13,000 per “COVID” patient, $39,000 for putting a patient on a ventilator, and an additional 20% bonus on the hospital bill for administering remdesivir. These claims, if substantiated, would indicate a potential conflict of interest in treatment protocols.

Future Trends in Pandemic Response and Drug Development

The remdesivir experience highlights several key areas for improvement in future pandemic responses:

Accelerated Drug Development and Clinical Trials

The rapid development and initial success of remdesivir demonstrate the potential for quickly mobilizing research and clinical trials during a public health crisis. However, it also underscores the need for rigorous, transparent data analysis and ongoing monitoring of drug safety and efficacy.

Addressing Misinformation and Building Public Trust

The spread of misinformation surrounding remdesivir and Dr. Fauci illustrates the critical importance of combating false narratives and building public trust in scientific expertise. Effective communication strategies and collaboration with social media platforms are essential to ensure accurate information reaches the public.

Transparency in Healthcare Funding and Incentives

The allegations of financial incentives influencing treatment decisions emphasize the need for greater transparency in healthcare funding and reimbursement models. Clear guidelines and ethical frameworks are necessary to prevent conflicts of interest and ensure patient care remains the top priority.

FAQ

What are your thoughts on the evolving landscape of pandemic treatments? Share your comments below!